The Cambridge, Mass.-based company on Thursday said it will now focus on in vivo Crispr-edited medicines based on its researchers recent scientific progress in multiple tissues. At the same time, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback